329 related articles for article (PubMed ID: 31201616)
21. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
Trautman H; Szabo E; James E; Tang B
J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
[TBL] [Abstract][Full Text] [Related]
22. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
23. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
MacDonald K; Alrawashdh N; McBride A; Abraham I
Future Oncol; 2021 Nov; 17(33):4561-4570. PubMed ID: 34382416
[TBL] [Abstract][Full Text] [Related]
24. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Grewal S; Ramsey S; Balu S; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
[TBL] [Abstract][Full Text] [Related]
25. Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.
Jang M; Simoens S; Kwon T
BioDrugs; 2021 Jan; 35(1):89-101. PubMed ID: 33368051
[TBL] [Abstract][Full Text] [Related]
26. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
[TBL] [Abstract][Full Text] [Related]
27. Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.
Heng JE; Raman S; Wong ZY; Beh VJN
Daru; 2024 Jun; 32(1):67-76. PubMed ID: 37903943
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
29. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
Abraham I; Han L; Sun D; MacDonald K; Aapro M
Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
[TBL] [Abstract][Full Text] [Related]
30. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
[TBL] [Abstract][Full Text] [Related]
31. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
McBride A; Balu S; Campbell K; Bikkina M; MacDonald K; Abraham I
Future Oncol; 2017 Oct; 13(25):2285-2295. PubMed ID: 28870106
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
34. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
35. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
[TBL] [Abstract][Full Text] [Related]
36. Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.
Liu Y; Yang M; Garg V; Wu EQ; Wang J; Skup M
Adv Ther; 2019 Aug; 36(8):1851-1877. PubMed ID: 31168766
[TBL] [Abstract][Full Text] [Related]
37. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action of the trastuzumab biosimilar CT-P6.
Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
[No Abstract] [Full Text] [Related]
39. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
40. Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
Horn DM; Alpert AE; Duggan MG; Garcia NA; Jacobson M
JCO Oncol Pract; 2023 Apr; 19(4):e476-e483. PubMed ID: 36638330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
